First patient dosed in bemcentinib COVID-19 trial
Bemcentinib was selected as the first candidate to be tested as part of the UK ACcelerating COVID-19 Research & Development platform (ACCORD) study
Read More
Tag: ACCORD
Bemcentinib first candidate to be tested in unique ACCORD study
ACCORD is a multicentre, seamless, Phase II adaptive randomisation platform trial to assess the efficacy and safety of multiple candidate agents
Read More
Teva divests UK, Ireland assets
Teva Pharmaceutical Industries is planning to sell off assets and operations of Actavis Generics in the UK and Ireland to Intas Pharmaceuticals subsidiary Accord Healthcare for £603 million.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
